首页> 外文期刊>Materials science & engineering >TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance
【24h】

TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance

机译:TPGS功能化的介孔二氧化硅纳米粒子用于抗癌药物递送,以克服多药耐药性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Multidrug resistance (MDR) has become a very serious problem in cancer therapy. To effectively reverse MDR in tumor treatments, a new pH-sensitive nano drug delivery system (NDDS) composed of mesoporous silica nanoparticles (MSNs) andd-a-tocopheryl poly-ethylene glycol 1000 succinate (TPGS) copolymers was synthesized to deliver doxorubicin (DOX) into drug-resistant breast cancer cell line (MCF-7/ADR). DOX@MSNs-TPGS were characterized to have a single peak size distribution, high DOX loading efficiency and a pH-dependent drug release profile. MSNs-TPGS were internalized via caveolae, clathrin-mediated endocytosis and energy-dependent cellular uptake. The DOX@MSNs-TPGS exhibited 10-fold enhanced cell killing potency compared to free DOX and DOX@MSNs. The enhanced MDR reversal effect was ascribed to the higher amount of cellular uptake of DOX@MSNs-TPGS in MCF-7/ADR cells than that of free DOX and DOX@MSNs, as a result of the inhibition of P-gp mediated drug efflux by TPGS. In vivo studies of NDDS in tumor-bearing mice showed that DOX@MSNs-TPGS displayed better efficacy against MDR tumors in mice and reached the tumor site more effectively than DOX and DOX@MSNs, with minimal toxicity. These results suggest DOX@MSNs-TPGS developed in this study have promising applications to overcome drug resistance in tumor treatments.
机译:多药耐药性(MDR)已成为癌症治疗中非常严重的问题。为了在肿瘤治疗中有效逆转MDR,合成了一种新的pH敏感的纳米药物递送系统(NDDS),该系统由介孔二氧化硅纳米颗粒(MSN)和d-α-生育酚聚乙二醇1000琥珀酸酯(TPGS)共聚物组成,可以递送阿霉素(DOX) )进入耐药乳腺癌细胞系(MCF-7 / ADR)。 DOX @ MSNs-TPGS具有单峰尺寸分布,高DOX加载效率和pH依赖性药物释放曲线的特征。 MSNs-TPGS通过小窝,网格蛋白介导的内吞作用和能量依赖性细胞摄取而被内化。与自由的DOX和DOX @ MSNs相比,DOX @ MSNs-TPGS的细胞杀伤力提高了10倍。 MDR逆转作用的增强归因于MCF-7 / ADR细胞中DOX @ MSNs-TPGS的细胞摄取量高于游离DOX和DOX @ MSNs,这是由于P-gp介导的药物流出被抑制的结果由TPGS。 NDDS在荷瘤小鼠体内的研究表明,DOX @ MSNs-TPGS对小鼠的MDR肿瘤显示出更好的疗效,并且比DOX和DOX @ MSNs更有效地到达肿瘤部位,且毒性最小。这些结果表明,在这项研究中开发的DOX @ MSNs-TPGS在克服肿瘤治疗中的耐药性方面具有广阔的应用前景。

著录项

  • 来源
    《Materials science & engineering》 |2018年第3期|108-117|共10页
  • 作者单位

    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia;

    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia;

    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia;

    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia;

    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia;

    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia;

    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin Medical University;

    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    TPGS; P-gp inhibition; Multidrug resistance; Mesoporous silica nanoparticles (MSNs); Doxorubicin;

    机译:TPGS;P-gp抑制;多药耐药性;介孔二氧化硅纳米粒子(MSNs);阿霉素;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号